Trump announces 100% chip tariff as Apple ups U.S. investment
Eric M. Dube, the Chief Executive Officer of Travere Therapeutics, Inc. (NASDAQ:TVTX), recently executed a notable stock transaction amid the company’s impressive 227% stock surge over the past year. On May 5, 2025, Dube sold 18,924 shares of Travere Therapeutics at a price of $21.05 per share, totaling approximately $398,350. According to InvestingPro data, the company currently has a market capitalization of $1.9 billion. This transaction was part of a pre-arranged trading plan established on March 15, 2024, which complies with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
The sale followed a vesting of performance-based restricted stock units (PSUs) on May 2, 2025. These PSUs, granted on January 31, 2022, vested after the company confirmed it met specific performance criteria related to cumulative FILSPARI net revenue for the quarter ended March 31, 2025. As a result, Dube acquired 18,924 shares of common stock, which were subsequently sold to cover tax obligations arising from the vesting.
Following these transactions, Dube’s direct ownership in Travere Therapeutics stands at 419,173 shares.
In other recent news, Travere Therapeutics Inc. reported its first-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.19, compared to the forecasted -$0.55. The company also exceeded revenue projections, posting $81.7 million against an expected $78.05 million. Travere’s flagship product, FILSPARI, showed significant growth, achieving net sales of $55.9 million, marking a 182% increase compared to the previous year. The company reported a net loss of $41.2 million, or $0.47 per share, reflecting ongoing investments in research and development.
Travere Therapeutics is preparing for a potential FDA approval for a new indication for FILSPARI, which could expand its market. The company’s strong performance in Q1 2025 was highlighted by a 90% year-over-year growth in total revenue. Additionally, Travere anticipates continued growth in FILSPARI sales throughout 2025 and is preparing for an FDA decision on the FSGS indication in September. The company expects to receive milestone payments from partnerships, which should enhance its financial flexibility.
Despite the positive earnings results, Travere’s stock experienced a minor decline. The muted market reaction may indicate investor caution or profit-taking following the earnings report. Travere continues to focus on expanding its commercial infrastructure to support future product launches, including potential new indications for FILSPARI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.